Directorate Change

4D pharma plc

(the "Company" or "4D")

Directorate Change

4D announces the resignation from its board of Thomas Engelen, Non-executive Director, for personal reasons with effect from 20 May 2020.

Duncan Peyton, CEO, commented: "On behalf of the Board, I would like to express our gratitude to Thomas for the contribution made during his tenure, which stretches back to the flotation of the Company in 2014. We wish him the very best for the future."

The 4D Board has four continuing non-executive directors, three of which are deemed to be independent, including the Chairperson, Professor Dr. med. Axel Glasmacher. As such, the Board will comprise a total of six directors, with the independent Chairperson holding a casting vote.

About 4D

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical studies in progress, namely a Phase II clinical study of BLAUTIX® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

Contact Information:

4D

Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130

Investor Relations [email protected]

N+1 Singer - Nominated Adviser and Joint Broker +44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Image Box PR

Neil Hunter / Michelle Boxall

Tel +44 (0)20 8943 4685

[email protected] / [email protected]